Neurons die earlier than experts previously thought in Alzheimer’s disease, and stopping the process could prevent the disease from ever developing, finds a new study from Tokyo Medical and Dental University in Japan. Research brings a new understanding of how Alzheimer’s disease develops. Alzheimer’s disease is the leading cause of dementia, and as many as...
Discovered in mice and confirmed in human samples, scientific team become the first to observe how a characteristic of the Presenilin1 gene means it could be used as a biomarker for Alzheimer’s TAYLOR & FRANCIS GROUP Scientists have detected that a previously overlooked gene behavior could potentially lead to a new way to diagnose Alzheimer’s...
Memory loss is the most common symptom of Alzheimer’s disease, but many patients also experience problems with language, spatial awareness, and other cognitive functions, particularly as the disease progresses. Understanding the biological differences that drive these distinct symptoms could lead to more personalized patient care and potentially therapies targeted to patients’ individual needs. A new...
by Alzheimer’s Research UK Over a third of people would want to know they had Alzheimer’s disease 15 years before symptoms show, according to new findings from Alzheimer’s Research UK. The UK’s leading dementia research charity published a report, Detecting and diagnosing Alzheimer’s disease, revealing the public’s attitudes toward early detection and diagnosis of Alzheimer’s,...
By IOS PRESS A new study published in the Journal of Alzheimer’s Disease (JAD) on January 13, 2020, supports a growing body of research that links human exposure to aluminum with Alzheimer’s disease (AD). Researchers found significant amounts of aluminum content in brain tissue from donors with familial AD. The study also found a high...
Researchers say newly found protein is bio-marker for disease; suggest suppression of ‘aggregatin’ could lead to future treatments to slow Alzheimer’s progression CASE WESTERN RESERVE UNIVERSITY CLEVELAND–Researchers at the Case Western University School of Medicine say they have identified a previously unknown gene and associated protein which could potentially be suppressed to slow the advance...
by Gladstone Institutes Gladstone researchers, in collaboration with Genentech, a member of the Roche group, have shown therapeutic efficacy of a new experimental drug in mouse models of Alzheimer’s disease and a rare genetic form of epilepsy known as Dravet syndrome. The small molecule increases the activity of a subset of neurotransmitter (NMDA) receptors that...
Bridget M. Kuehn, MSJ JAMA. Published online January 8, 2020. doi:10.1001/jama.2019.20939 Areas or patterns of reduced glucose metabolism are often seen in brain scans of patients with Alzheimer disease and other dementias. Now, a growing body of evidence suggests that glucose hypometabolism may be more than just a biomarker on brain scans: it may be a key...
It may open the door to new treatments and explain why previous ones failed By Karen Weintraub on January 16, 2020 Alzheimer’s disease has long been characterized by the buildup of two distinct proteins in the brain: first beta-amyloid, which accumulates in clumps, or plaques, and then tau, which forms toxic tangles that lead to...
Individuals with Alzheimer’s disease prefer taking part in familiar activities that are emotionally meaningful over strictly task-oriented activities, new research shows. University of Alberta researchers conducted a study published in Aging and Mental Health in which, for the first time, people with Alzheimer’s disease were directly asked what they preferred to do. The researchers found...
